These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28248817)

  • 1. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
    Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
    Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma.
    Motohara T; Tashiro H; Miyahara Y; Sakaguchi I; Ohtake H; Katabuchi H
    Cancer Sci; 2010 Jun; 101(6):1550-6. PubMed ID: 20384630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.
    Gockley A; Melamed A; Bregar AJ; Clemmer JT; Birrer M; Schorge JO; Del Carmen MG; Rauh-Hain JA
    Obstet Gynecol; 2017 Mar; 129(3):439-447. PubMed ID: 28178043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
    Jönsson JM; Johansson I; Dominguez-Valentin M; Kimbung S; Jönsson M; Bonde JH; Kannisto P; Måsbäck A; Malander S; Nilbert M; Hedenfalk I
    PLoS One; 2014; 9(9):e107643. PubMed ID: 25226589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study.
    Baba T; Koshiyama M; Kagabu M; Mikami Y; Minamiguchi S; Moritani S; Ishikawa M; Okamoto A; Terao Y; Nakanishi T; Katabuchi H; Tokunaga H; Satoh T; Konishi I; Yaegashi N
    Int J Clin Oncol; 2023 Oct; 28(10):1411-1420. PubMed ID: 37526805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic Genomic and Transcriptomic Characterization of Primary Ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
    J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node involvement in an ovarian borderline serous tumor: a rare clinicopathologic presentation with management dilemma.
    Aggarwal D; Gupta P; Bagga R; Srinivasan R; Das CK
    Am J Transl Res; 2023; 15(11):6667-6672. PubMed ID: 38074826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Review of Serous Tumors of Tubo-Ovarian Origin: Clinical Behavior, Pathological Correlation, Current Molecular Updates, and Imaging Manifestations.
    Folsom SM; Berger J; Soong TR; Rangaswamy B
    Curr Probl Diagn Radiol; 2023; 52(5):425-438. PubMed ID: 37286440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis, treatment, and follow-up of borderline ovarian tumors.
    Fischerova D; Zikan M; Dundr P; Cibula D
    Oncologist; 2012; 17(12):1515-33. PubMed ID: 23024155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of BRCA1 Expression on Survival Status in Ovarian Serous Carcinoma of Egyptian Patients.
    Amin NH; Ahmed BA; Abou-Bakr AA; Eissa SS; Nassar HR; Gad M; Eissa M
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3613-3620. PubMed ID: 37898870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Malignant Potential of Ovarian Steroid Cell Tumors Revisited: A Multi-institutional Clinicopathologic Analysis of 115 Cases.
    Fadare O; Fard EV; Bhargava R; Desouki MM; Hanley KZ; Ip PPC; Li JJX; Lu B; Medeiros F; Ng JHY; Parkash V; Pinto A; Quick CM; Skala SL; Tokuyama M; Turashvili G; Wei CH; Xing D; Zheng W; Soong TR; Howitt BE
    Am J Surg Pathol; 2024 May; 48(5):570-580. PubMed ID: 38512100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women.
    Kristensen AK; Frandsen CLB; Nøhr B; Viuff JH; Hargreave M; Frederiksen K; Kjær SK; Jensen A
    Gynecol Oncol; 2024 Jun; 185():108-115. PubMed ID: 38382167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
    Manning-Geist BL; Sullivan MW; Zhou Q; Iasonos A; Selenica P; Stallworth C; Liu YL; Long Roche K; Gordhandas S; Aghajanian C; Chi D; O'Cearbhaill R; Grisham RN; Chui MH
    Gynecol Oncol; 2024 Jun; 188():52-57. PubMed ID: 38941962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Grade Serous Ovarian Carcinoma: a Retrospective Study from a Tertiary Cancer Institute.
    Nuthalapati S; Kundargi RS; Reddihalli PV; Rathod PS; Krishnappa S
    Indian J Surg Oncol; 2022 Dec; 13(4):707-715. PubMed ID: 36687250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophilic Cells in Ovarian Borderline Serous Tumors as a Predictor of BRAF Mutation.
    Badlaeva A; Tregubova A; Palicelli A; Asaturova A
    Cancers (Basel); 2024 Jun; 16(13):. PubMed ID: 39001384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
    Charbonneau B; Moysich KB; Kalli KR; Oberg AL; Vierkant RA; Fogarty ZC; Block MS; Maurer MJ; Goergen KM; Fridley BL; Cunningham JM; Rider DN; Preston C; Hartmann LC; Lawrenson K; Wang C; Tyrer J; Song H; deFazio A; Johnatty SE; Doherty JA; Phelan CM; Sellers TA; Ramirez SM; Vitonis AF; Terry KL; Van Den Berg D; Pike MC; Wu AH; Berchuck A; Gentry-Maharaj A; Ramus SJ; Diergaarde B; Shen H; Jensen A; Menkiszak J; Cybulski C; Lubiłski J; Ziogas A; Rothstein JH; McGuire V; Sieh W; Lester J; Walsh C; Vergote I; Lambrechts S; Despierre E; Garcia-Closas M; Yang H; Brinton LA; Spiewankiewicz B; Rzepecka IK; Dansonka-Mieszkowska A; Seibold P; Rudolph A; Paddock LE; Orlow I; Lundvall L; Olson SH; Hogdall CK; Schwaab I; du Bois A; Harter P; Flanagan JM; Brown R; Paul J; Ekici AB; Beckmann MW; Hein A; Eccles D; Lurie G; Hays LE; Bean YT; Pejovic T; Goodman MT; Campbell I; Fasching PA; Konecny G; Kaye SB; Heitz F; Hogdall E; Bandera EV; Chang-Claude J; Kupryjanczyk J; Wentzensen N; Lambrechts D; Karlan BY; Whittemore AS; Culver HA; Gronwald J; Levine DA; Kjaer SK; Menon U; Schildkraut JM; Pearce CL; Cramer DW; Rossing MA; Chenevix-Trench G; ; ; Pharoah PD; Gayther SA; Ness RB; Odunsi K; Sucheston LE; Knutson KL; Goode EL
    Cancer Immunol Res; 2014 Apr; 2(4):332-40. PubMed ID: 24764580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Borderline ovarian tumours: CNGOF Guidelines for clinical practice - Biopathology of ovarian borderline tumors].
    Eymerit-Morin C; Brun JL; Vabret O; Devouassoux-Shisheboran M
    Gynecol Obstet Fertil Senol; 2020 Sep; 48(9):629-645. PubMed ID: 32422414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma.
    Chen H; Gotimer K; De Souza C; Tepper CG; Karnezis AN; Leiserowitz GS; Chien J; Smith LH
    Gynecol Oncol; 2020 Jun; 157(3):783-792. PubMed ID: 32253045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Into the future: A pilot study combining imaging with molecular profiling to predict resectability in ovarian cancer.
    Kumar A; Wang C; Sheedy SP; McCauley BM; Winham SJ; Ramus SJ; Anglesio MS; Kim B; Torres D; Keeney GL; Cliby WA; Goode EL
    Gynecol Oncol; 2022 Sep; 166(3):508-514. PubMed ID: 35931468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes.
    Robertson SE; Yasukawa M; Marchion DC; Xiong Y; Naqvi SMH; Gheit T; Tommasino M; Wenham RM; Giuliano AR; Lancaster JM; Shahzad MMK
    PLoS One; 2023; 18(12):e0294448. PubMed ID: 38039311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.